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Neurodegenerative diseases with distinct genetic etiologies and pathological phenotypes appear to share
common mechanisms of neuronal cellular dysfunction, including excitotoxicity, calcium dysregulation,
oxidative damage, ER stress and mitochondrial dysfunction. Glial cells, including microglia and astro-
cytes, play an increasingly recognized role in both the promotion and prevention of neurodegeneration.
Sigma receptors, particularly the sigma-1 receptor subtype, which are expressed in both neurons and glia
of multiple regions within the central nervous system, are a unique class of intracellular proteins that can
modulate many biological mechanisms associated with neurodegeneration. These receptors therefore
represent compelling putative targets for pharmacologically treating neurodegenerative disorders. In this
review, we provide an overview of the biological mechanisms frequently associated with neuro-
degeneration, and discuss how sigma-1 receptors may alter these mechanisms to preserve or restore
neuronal function. In addition, we speculate on their therapeutic potential in the treatment of various
neurodegenerative disorders.
© 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neurodegeneration is characterized by the progressive loss of
neuronal integrity, in both structure and function. Alzheimer's
disease and Parkinson's disease are the most common neurode-
generative disorders worldwide, affecting approximately 10% of
individuals over the age of 60. Current therapies for these and other
neurodegenerative conditions focus on symptomatic treatment,
and there remains an urgent need to identify and develop effective
therapeutics to protect and restore neuronal integrity. To achieve
this goal, a better understanding of cellular targets and processes
involved in neurodegeneration and regeneration is needed.rnia, College of Pharmacy,
umoto).
rmacological Society.
r B.V. on behalf of Japanese PharmAmong the putative therapeutic targets being studied, sigma
receptors have gained attention for their involvement in modu-
lating cell survival and function. Originally misclassiﬁed as a sub-
type of opioid receptor in the 1970s, sigma receptors are now
recognized as a unique class of intracellular proteins, distinct from
G protein-coupled and ionotropic receptors (1). They are capable of
modulating a variety of cellular processes relevant to neuro-
degeneration (1,2). The two established subtypes, sigma-1 and
sigma-2, are both highly expressed in the central nervous system
(CNS), and can be distinguished by their distinct pharmacological
proﬁles and molecular characteristics (1).
Over the past decade, signiﬁcant advances have been made in
our understanding of the sigma-1 receptor subtype in both patho-
logical and physiological processes. The contribution of the sigma-2
subtype, however, remains less well understood due to the paucity
of available experimental tools to study its functions. This review
focuses on the role of sigma-1 receptors in neurodegeneration,acological Society. This is an open access article under the CC BY-NC-ND license
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lowed by a summary of the common mechanisms of neuro-
degeneration and how sigma-1 receptor ligands may modulate
these mechanisms to elicit neuroprotective and/or restorative ef-
fects. Finally, we discuss the potential application of sigma-1 re-
ceptor modulation to speciﬁc therapeutic interventions.
2. Sigma-1 receptor structure and functions
The sigma-1 receptor is a small (28 kDa), highly conserved,
transmembrane protein located in the endoplasmic reticulum (ER)
membrane. It is speciﬁcally enriched in the ER subregion contacting
mitochondria, called the mitochondrial-associated membrane
(MAM). Localization studies also report the sigma-1 receptor at or
in i) neuronal nuclear, mitochondrial, and plasma membranes, ii)
multiple other CNS cell types (astrocytes, microglia and oligoden-
drocytes), and iii) CNS-associated immune and endocrine tissues
(1). The varied sites at which sigma-1 receptors are present suggest
multiple pathways by which these receptors may inﬂuence physi-
ological and pathological processes.
The sigma-1 receptor can migrate between different organellar
membranes in response to ligand binding (3,4). As chaperone
proteins, sigma-1 receptors do not have their own intrinsic
signalingmachinery. Instead, upon ligand activation, they appear to
operate primarily via translocation and protein-protein in-
teractions to modulate the activity of various ion channels and
signaling molecules, including inositol phosphates, protein kinases,
and calcium channels (3). The characteristics of sigma-1 in-
teractions in each pathway are still being determined.
Because sigma-1 receptors exhibit no homology to other
mammalianproteins, geneticmanipulation has been instrumental in
investigating their functions in experimental systems. These studies
allow the results of pharmacological manipulation, which is more
amenable for potential therapeutic intervention, to be interpreted as
either agonistic or antagonistic. By convention, “antagonists” are
those compounds that recapitulate the gene knockdownphenotype;
they generally have no effects on their own, but attenuate the effects
of sigma-1 stimulation. Sigma-1 receptor antagonists that are
commonly cited in the literature, including this review, include:
BD1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethyla-
mino) ethylamine), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-
methylpiperazine), and NE-100 (4-methoxy-3-(2-phenylethoxy)-
N,N-dipropylbenzeneethanamine). In contrast, sigma-1 “agonists”
are those compounds that recapitulate the phenotypes of receptor
overexpression, either autonomously or additive to the effects of
other compounds. Common selective sigma-1 receptor agonists
include: (þ)-pentazocine, (þ)-SKF10,047, PRE084 (2-morpholin-4-
ylethyl 1-phenylcyclohexane-1-carboxylate), and SA4503 (1-[2-
(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine). Many
currently marketed drugs (e.g., haloperidol, donepezil, and ﬂuvox-
amine) interact with sigma-1 receptors, but are not selective for
them. The involvement of the sigma-1 subtype in a given system
therefore requires careful analysis and veriﬁcation using selective
genetic and pharmacological tools.
3. Common mechanisms of neurodegeneration
3.1. Excitotoxicity and calcium overload
Glutamate is the major excitatory neurotransmitter in the CNS,
and its interaction with speciﬁc membrane receptors is responsible
for many neurologic functions, including learning and memory.
Sustained release of glutamate, however, causes persistent (and
only partially desensitizable) activation of N-methyl-D-aspartate
(NMDA) receptors, leading to neuronal excitotoxicity. In addition totransporting sodium, NMDA receptors also transport calcium.
Persistent activation therefore increases intracellular calcium
levels, followed by stochastic failure of calcium homeostasis and
necrotic cell death (5). This toxicity does not result from superoxide
free radical production, as initially proposed (6), but rather from
activation of the mitochondrial permeability transition pore
opening triggered by membrane potential-dependent uptake of
calcium into themitochondrial matrix (7,8). The identity of the pore
itself has recently been proposed to be the Fo portion of the FoF1
adenosine triphosphate (ATP) synthase (9). Excitotoxicity and
excess intracellular calcium contribute to neurodegeneration in
many acute CNS diseases, including stroke and traumatic brain
injury, and are also implicated in chronic diseases, including
amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Par-
kinson's disease (5,10,11).
3.2. Oxidative and nitrosative stress
Oxygen (O2) is critical to meet the energetic demands of bio-
logical tissues through the production of ATP by oxidative phos-
phorylation. However, aberrant O2 reduction produces radical
species that can cause extensive damage to cellular components,
cells, and tissues. This phenomenon of “oxidative stress” is deﬁned
by a broad range of phenotypes, including the accumulation of
oxidized molecules and the disruption of normal cellular processes
and viability. Oxidative stress is typically considered to be the state
inwhich these phenotypes aremeasurable at higher levels than in a
“normal” state. Neuronsmay be particularly vulnerable to oxidative
stress due to their terminally differentiated state, complex
morphology, and dependence on surrounding glia for metabolic
substrates and glutathione (12). Reactive oxygen species (ROS) are
generated by multiple conditions and sources, including sustained
neurotransmission (e.g., of glutamate, dopamine, or serotonin),
mitochondrial dysfunction, and production by glial cells. Depend-
ing on the species and location of the ROS, oxidative damage can
affect nucleic acids, proteins and lipids. The best evidence that ROS
may be an underlying cause of neurodegeneration is the strong
association between the detection of increased ROS production and
the increased oxidative damage observed in CNS disorders such as
Parkinson's disease, Alzheimer's disease and ALS (12,13). Oxidative
stress can also impair mitochondrial function, leading to a deple-
tion of ATP and decreased antioxidant capacity (13). Along with
ROS, reactive nitrogen species (RNS) can also be generated under
pathological conditions in the CNS.
3.3. Endoplasmic reticulum (ER) stress
The ER plays an important role in protein synthesis and folding
as well as cellular homeostasis. Different perturbations, such as
calcium dysregulation and oxidative stress, can alter ER function
and lead to the accumulation of unfolded or misfolded proteins
within the ER lumen. This triggers a stress response by the ER
known as the unfolded protein response (UPR) to restore protein
folding homeostasis (Fig. 1). Three major signaling pathways
mediate the UPR: protein kinase RNA-like ER kinase (PERK),
inositol-requiring enzyme 1 alpha (IRE1a), and activating tran-
scription factor 6 (ATF6).
The downstream activities of all three pathways have been
implicated in protective or adaptive responses to the protein
accumulation as well as in the promotion of apoptosis. Adaptive
responses include a reduction in global protein translation by PERK
to decrease the protein load to the ER, and an upregulation of
proteins involved in the UPR by IRE1a and ATF6 to increase ER
folding capacity and ER-associated protein degradation (ERAD).
Conversely, PERK activation can also lead to apoptosis. Some
Fig. 1. Schematic diagram of the unfolded protein response (UPR) and modulation by sigma-1 receptors (adapted from (14)). Accumulation of misfolded or unfolded proteins in the
endoplasmic reticulum (ER) activates the UPR to restore protein folding homeostasis and promote cell survival (adaptive response). Prolonged exposure to ER stress overcomes the
adaptive response of the UPR and induces apoptosis (pro-apoptotic response). See text for details and further information (Section 3.3). To promote cell survival, sigma-1 receptors
have been reported to modulate the activity and/or levels of the three major ER stress proteins (PERK, IRE1a, and ATF6), decrease CHOP, BAX and caspases and increase Bcl-2, as
discussed in the text (Section 4.3 and Section 5) and represented here by yellow boxes.
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translational repression. ATF4 then promotes the expression of
various apoptotic activators, including C/EBP-homologous protein
(CHOP). Sustained activation of PERK thus leads to the CHOP
upregulation, which in turn inhibits the expression of anti-
apoptotic Bcl-2 while upregulating expression of the pro-
apoptotic BH3-only proteins. This cascade of events can result in
the activation of Bak- and Bax-dependent apoptosis (14). IRE1a can
also induce the activation of c-JUN amino-terminal kinase (JNK)
and apoptosis signal-regulating kinase 1 (ASK1) and degrade
microRNAs that inhibit caspase expression, contributing to
caspase-activated apoptotic cell death (14). Additionally, ATF6 can
decrease Bcl-2 levels and increase cytochrome C release, adding to
the activation of the apoptotic cascade (15).
Whether ER stress elicits a UPR-adaptive or pro-apoptotic
response depends on the accumulation of misfolded proteins and
the timing of the stress exposure (14). Under acute stress and
moderate misfolded protein accumulation, the UPR is activated to
clear accumulations through the ERAD machinery linked to the
ubiquitin proteasome system (UPS) or through autophagy,
restoring cellular homeostasis (14). Although the threshold for
apoptosis is unclear, it is reasonable to assume that prolonged or
severe protein accumulation could cause the ER to trigger cell deathrather than cell maintenance programs. Consistent with this,
constitutive activity of the ER stress response has been linked to
neurodegenerative diseases such as Alzheimer's disease, Parkin-
son's disease, and Huntington's disease (14,16). Therapeutic stra-
tegies predicted to inhibit neurodegeneration might enhance UPR
signaling responses that attenuate ER stress inducers, while
inhibiting those portions of UPR signaling that promote apoptosis.
3.4. Mitochondrial dysfunction
Mitochondria play multiple critical roles in neuron mainte-
nance. In addition to supplying ATP and providing metabolic and
biosynthetic substrates, mitochondria also regulate calcium ho-
meostasis and the initiation of apoptosis. Aberrant mitochondrial
function is associated with multiple neurodegenerative diseases
(13,17).
As described above, high intracellular calcium as a result of
sustained glutamate receptor activity is a proposed trigger for
excitotoxic cell death. This process is dependent on polarized
mitochondria; cells treated with mitochondrial inhibitors are not
susceptible to the calcium deregulation that mediate excitotoxicity
(18), though the artiﬁcial conditions that confer this protection
would result in ATP insufﬁciency that in vivo would not be feasible.
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a key role for spare respiratory capacity, or the ability of the cell to
increase respiration beyond its basal rate to meet increased ATP
demand. In the context of sustained glutamate signaling, the inﬂux
of sodium along with calcium through the NMDA receptor require
increased activity of the sodium-potassium ATPase to restore
resting ion concentrations (18), increasing ATP demand and
requiring ATP production to increase. Indeed, pharmacological in-
hibition of respiratory capacity increases the stochastic failure of
cell viability under these conditions, suggesting ATP insufﬁciency
upstream of calcium dysregulation as the initial trigger of the
excitotoxic cascade.
Alterations in mitochondrial structure and dynamics are also
strongly associated with neurodegenerative diseases. Mitochon-
drial ﬁssion and fusion are part of normal organellar maintenance,
allowing mitochondrial transport to distal regions of the cell.
Fission and fusion are particularly signiﬁcant in axons, in which
mitochondria may have to travel long distances. These processes
also allow the sequestration of damagedmitochondrial material for
engulfment by autophagosomes (19). Multiple diseases are asso-
ciated with defects of either fusion or ﬁssion, though causality is
not always clear. In addition, genetic or RNA-level disruption of
proteins that mediate ﬁssion and fusion can recapitulate multiple
disease phenotypes.
Recent work has identiﬁed the ER as a crucial component of the
mitochondrial ﬁssion machinery, where dynamin-related protein 1
(Drp1) is recruited to ER-mitochondria contact sites and mediates
ﬁssion (20). Homozygous knockout of Drp1 is lethal (21), while
fragmented mitochondria and elevated or modiﬁed Drp1 (i.e.,
increased ﬁssion activity) are associated with Alzheimer's disease,
Parkinson's disease, and Huntington's disease (17). The close
apposition of mitochondria to a particular subset of the ER, the
MAM, is important for multiple other aspects of normal mito-
chondrial and cellular function. Proper interaction between mito-
chondria and the MAM maintains lipid synthesis and trafﬁcking,
calcium homeostasis, and regulation of mitochondrial-dependent
apoptosis. Mitochondria-MAM dysregulation has been proposed
as the underlying cause of Alzheimer's disease (22), and may
contribute to neuronal loss in other disease contexts (23).
3.5. Reactive gliosis
Neural tissue insults arise from various sources and involve
nearly all cell types contained within the CNS. One of the most
ubiquitous responses to CNS insults including neurodegenerative
disorders is reactive gliosis (24). Although present in awide array of
neurodegenerative disorders, its contribution to neuro-
degeneration and the progression of neurodegenerative disorders
is still poorly understood.
Reactive astrogliosis is classiﬁed as the “activation” of astrocytes
within the CNS. This activation leads to the increased expression of
various genes, including glial ﬁbrillary acidic protein (GFAP), a
component of astrocytic ﬁlaments and commonly utilized marker
of reactive astrogliosis. The upregulation of GFAP is a downstream
result of STAT3 (signal transducer and activator of transcription 3)
phosphorylation and activation, an effect demonstrated in multiple
models of neurodegenerative disorders (25). Neural damage that
results in astrogliosis and the subsequent upregulation of GFAP
causes astrocytes to proliferate, migrate, and in cases of severe
neural damage, form glial scars (25,26). Glial scar formation is hy-
pothesized to protect surrounding neuronal tissue from further
damage as a result of excess inﬂammation; however the formation
of glial scars also can impede repair processes and thereby can
inhibit the ability of neuronal tracts to regenerate (25). Reactive
astrocytes can also produce several factors (cytokines, chemokines,and neurotrophic factors) to further improve or aggravate brain
damage (25).
Microglia are a separate and distinct type of glial cell compared
to astrocytes. They are the macrophage-derived resident immune
cells of the CNS. Under normal physiological conditions, microglia
are responsible for synaptic pruning, ultimately affecting neuronal
connectivity and signaling (27). The ability of microglia to monitor
the surrounding microenvironment and react to both changes in
neuronal signaling as well as CNS insults underlies their impor-
tance in neurodegeneration (28). As a result of disruptions in CNS
homeostasis, microglia are activated in a manner similar to mac-
rophages in the periphery (28). Although multiple microglial phe-
notypes are believed to occur in response to CNS insult, they are
typically classiﬁed as M1 and/or M2 responses, similar to periph-
eral macrophages (28). M1 microglial responses are pro-
inﬂammatory in nature, and can cause further damage to the CNS
through the release of ROS/RNS and pro-inﬂammatory cytokines
such as interleukin (IL)-1b, while M2 microglial responses are
believed to mediate repair, including remyelination, in response to
various CNS insults (28).
Further elucidation of precisely how the physiological changes
in astrocytes andmicroglia affect neurodegenerationmay provide a
framework for development of therapeutic strategies that target
endogenous regenerative processes. For example, interventions
aimed at limiting the inﬂammatory M1 response while enhancing
the reparative M2 responses may slow or even reverse the neuro-
degeneration that is characteristic of injury and disease
progression.
4. Neuroprotective actions by sigma ligands
4.1. Modulation of calcium homeostasis and glutamate activity
One major mechanism by which sigma-1 receptor ligands may
confer neuroprotection is through the regulation of intracellular
calcium homeostasis. The sigma-1 agonist (þ)-pentazocine, for
example, can induce a mono- or biphasic transient calcium
response in place of sustained ﬂux in primary rat cortical neurons
exposed to toxic concentrations of glutamate. This shift is indicative
of neuroprotection, possibly through modulation of receptor and
voltage-gated calcium channel activity (29). Additionally, sigma-1
agonists can attenuate intracellular calcium elevations in
response to an in vitro model of ischemia induced by sodium azide
and glucose deprivation (30). Notably, sigma-1 receptors can
respond to perturbations in ER calcium concentrations by pro-
moting calcium entry into mitochondria through stabilization of
type 3 inositol triphosphate (IP3) receptors (IP3R3) at the MAM (4).
Activation of sigma-1 receptors has also been shown to atten-
uate the release of glutamate following ischemia (31), and under
certain conditions inhibit NMDA receptors (32), which, among the
glutamate receptor subtypes, appear to be the principal mediators
of excitotoxic damage (10). The exact mechanisms by which
sigma-1 receptors modulate the activity of NMDA receptors is
unclear, but may involve direct interaction with speciﬁc subunits
of the NMDA receptor (33) or indirect effects of other ion channel
modulation (34).
4.2. Attenuation of reactive species production
Activation of sigma-1 receptors may also mitigate ROS accu-
mulation, possibly through modulation of ROS-neutralizing pro-
teins. Sigma-1 receptor knockout or knockdown can increase
oxidative damage (35,36). Liver and lung tissue homogenates as
well as primary hepatocytes extracted from sigma-1 knockoutmice
showed higher levels of superoxide as measured by an increased
L. Nguyen et al. / Journal of Pharmacological Sciences 127 (2015) 17e29 21ﬂuorescence of 20,70-dichloroﬂuorescin (DCF) compared to wild-
type mice (36). Metabolomic screening and 2D gel electrophoresis
of liver homogenates of the twomouse groups indicated signiﬁcant
differences in the levels of metabolites and proteins associatedwith
free radical production and clearance (36). Moreover, knockdown
of sigma-1 receptors in Chinese hamster ovary (CHO) cells caused
increased DCF ﬂuorescence intensity compared to control cells (35).
On the other hand, expression of sigma-1 receptors in monkey
kidney ﬁbroblast (COS-7) and mouse monocyte macrophage (RAW
264.7) cells led to decreased DCF ﬂuorescence intensity (36).
Addition of (þ)-pentazocine to COS-7 cells further attenuated the
ﬂuorescence signal, while the sigma antagonist haloperidol blocked
the expression phenotype, conferring higher ROS formation (36).
The apparent sigma-1-dependent decrease in ROS levels corre-
sponded with the upregulation of antioxidant response element
(ARE) genes including NAD(P): quinone oxidoreductase 1 (NQO1)
and superoxide dismutase 1 (SOD1) (36).
Sigma-1 agonists may also ameliorate nitrosative stress. The
sigma receptor agonist PPBP (4-phenyl-1-(4-phenylbutyl)piperi-
dine) attenuated nitric oxide (NO) production as well as nitrosative
damage to proteins and nucleic acids (37,38). The decrease in NO
generation may be linked to the ability of sigma-1 receptor acti-
vation to decrease nitric oxide synthase (NOS) activity (38e40).
4.3. Modulation of ER and mitochondrial function
Sigma-1 receptor localization within the ER and at mitochon-
drial membranes suggests a role in interorganellar communication
and regulation, as well as separate inﬂuences in each structure (4).
As chaperones, sigma-1 receptors can modulate the UPR. In its
dormant state, the sigma-1 receptor forms a complex at the MAM
with the ER chaperone and signaling regulator BiP/Grp78 (4).
During ER stress or via ligand stimulation, sigma-1 receptors
dissociate from BiP/Grp78 and can modulate the activity of other
proteins, including PERK, IRE1a, and ATF6 (4,41). In addition, ER
stress is associatedwith the upregulation of sigma-1 expression (4).
Overexpression of sigma-1 receptors has been shown to decrease
the activation of PERK and ATF6 and increase cell survival, whereas
knockdown of sigma-1 receptors destabilizes the conformation of
IRE1 and decreases cell survival following administration of the ER
stressor thapsigargin in vitro (4,41). The precise mechanism(s) by
which sigma-1 receptors may alter the activities or amounts of
these stress response proteins is unclear, but may involve direct
protein-protein interactions (41) and transcriptional regulation
(42,43). Future investigations must address the downstream effects
of sigma-1 receptor-mediated modulation on these stress response
proteins, and the timing of sigma-1 receptor regulation in response
to ER stress in order to better understand the conditions and timing
under which pharmacological modulation of sigma-1 may be of the
greatest beneﬁt.
Sigma-1 receptors may also alter mitochondrial function, as
sigma receptor ligands have been shown to ameliorate bioenergetic
deterioration in a variety of cells. For example, the sigma-1 receptor
ligand BHDP (N-benzyl-N-(2-hydroxy-3,4-dimethoxybenzyl)-
piperazine) protected rat liver cells from ischemic stress, preserving
mitochondrial respiration and ATP synthesis compared to the
control group (44). The cytoprotective effects of BHDP are likely
mediated through agonist activity at sigma-1 receptors, as similar
results were observed with the sigma-1 agonist SA4503 in car-
diomyocytes treated with angiotensin II to induce hypertrophy;
SA4503 protected cardiomyocytes from impaired ATP production
(45). Co-administration of the sigma-1 antagonist NE-100 blocked
this effect, conﬁrming speciﬁcity of sigma-1 receptor involvement
(45). Finally, in cultured astrocytes, BHDP overcame hypoxia-
induced impairment of ATP production (46).Sigma-1 receptors may confer these protective effects through
modulation ofmitochondrial calcium uptake at theMAM (4). Under
conditions of ER stress, sigma-1 receptors have been shown in CHO
cells to dissociate from BiP/Grp78 and interact directly with IP3R3,
which selectively mediates calcium uptake by mitochondria (4).
The sigma-1 receptor-IP3R3 interaction stabilizes IP3R3, which
could in turn promote both mitochondrial calcium uptake and,
ultimately, cell survival (4). Supporting this, Shioda and colleagues
identiﬁed a truncated splice variant of the sigma-1 receptor (short
form sigma-1 or sigma-1S) in the mouse hippocampus that local-
izes to the MAM and complexes with non-truncated sigma-1 re-
ceptors, but does not complex with IP3R (47). In mouse
neuroblastoma C3100 (Neuro-2a) cells, exogenous overexpression
of non-truncated sigma-1 receptors enhanced ATP- or IP3-induced
mitochondrial calcium uptake whereas overexpression of sigma-1S
decreased mitochondrial calcium uptake compared to control cells
(47). Following tunicamycin-induced ER stress, the exogenous
overexpression of non-truncated sigma-1 receptors protected IP3R
proteins from degradation and enhanced ATP production, pro-
moting cell survival (47). Conversely, overexpression of sigma-1S
enhanced IP3R degradation and decreased mitochondrial calcium
uptake, resulting in increased apoptosis (47). These ﬁndings sug-
gest that sigma-1S destabilizes IP3Rs and diminishes IP3R3-driven
mitochondrial calcium uptake through loss of sigma-1 IP3R3
interaction, resulting in impaired ATP production and increased
apoptosis (47). More work is needed to determine how truncated
sigma-1 receptors interfere with normal receptor function to affect
mitochondrial stability. This question is of high clinical relevance as
aberrant forms of sigma-1 receptors have been found to occur in
neurodegenerative conditions such as ALS (48,49).
Along with their effects on mitochondrial ATP production and
calcium mobilization, sigma-1 receptors may also inﬂuence the
expression of anti- and pro-apoptotic signals that target the mito-
chondria. Sigma-1 receptor activity positively regulates Bcl-2
expression, possibly through nuclear factor kappa B (NF-kB) and/or
extracellular signal-regulated kinase (ERK) pathways (42,50). In CHO
cells, the overexpression of sigma-1 receptors increases Bcl-2 mRNA
transcript and protein levels, while knockdown decreases Bcl-2
mRNA and protein and potentiates hydrogen peroxide-induced
apoptosis (50). Decreased Bcl-2 levels are also seen in retinal neu-
rons from sigma-1 receptor null mice (42). Additionally, pharma-
cological activation of sigma receptors with the sigma agonists PPBP
and afobazole protected cells against Bcl-2 decreases and apoptosis
induced by O2 or glucose deprivation, glutamate, or amyloid beta
(Ab) in primary cortical neurons (51,52). Since Bcl-2 has also been
shown to interact with IP3Rs and enhance their activity (53), this
positive regulation of Bcl-2 level may be another mechanism by
which sigma-1 activity increases IP3R-mediated mitochondrial cal-
cium uptake and ATP production, in addition to the sigma-1 re-
ceptor-IP3R interaction described above. Activation of sigma-1
receptors may also decrease expression of Bax and apoptosis-
associated caspases, further promoting cell survival (52,54).
4.4. Modulation of glial activity
Several recent studies have shown the ability of sigma ligands to
ameliorate reactive astrogliosis. For example, the sigma agonist 1,3-
di-(2-tolyl)guanidine (DTG) attenuated the increase in GFAP
expression that occurs in a rodent stroke model of middle cerebral
artery occlusion (MCAO) (55). Similar effects have been shown in a
mouse model of ALS, where treatment with the selective sigma-1
agonist PRE084 decreased GFAP immunoreactivity (56). Cellular
studies using cultured astrocytes appear to corroborate these
ﬁndings, as changes in sigma-1 receptor expression and ligands
targeting sigma receptors have been found to modulate the activity
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kinase 2 (JAK2)/STAT3 signaling pathway to inhibit astrocyte acti-
vation (59).
In addition to mitigating reactive astrogliosis, sigma ligands
have been shown to modulate microglial activity in animal models
of Parkinson's disease and ALS (11,56,60). Sigma ligands may affect
M1 and/or M2 microglial responses, though most studies to date
have focused more on the amelioration of the M1 type. In primary
cultures of microglia, the sigma agonists DTG and afobazole sup-
pressed microglial activation andmigration as well as the release of
inﬂammatory cytokines in response to microglial activators such as
ATP, uridine triphosphate, lipopolysaccharide (LPS), and monocyte
chemoattractant protein-1 (MCP-1) (61,62). Conversely, in animals
with motor neuron (MN) disease, treatment with the selective
sigma-1 agonist PRE084 increased the number of cells positive for
the pan-macrophage marker cluster of differentiation 68 (CD68)
and of CD206-positive cells, which are associated with neuronal
repair (56). Sigma ligands also improved microglial cell survival
during and 24 hours after ischemia (61) as well as after toxic
exposure with Ab (63). These data suggest that sigma receptors
may elicit neuroprotective and/or neurorestorative effects by
maintaining the proper balance of inﬂammatory and reparative
microglial responses. Additional studies are needed to determine
the effects mediated by speciﬁc sigma receptor subtypes on glial
function, as DTG and afobazole bind to both sigma-1 and sigma-2
receptors. Further elucidation of the mechanisms by which
sigma-1 receptors modulate glial activity is also warranted.
5. Potential therapeutic opportunities
5.1. Stroke
A major contributor to cerebral damage following stroke is
glutamate-mediated excitotoxicity (10). Sigma-1-preferring and
mixed sigma receptor agonists have been shown to decrease
glutamate release and block intracellular calcium overload
following ischemia in vitro (30,31). Moreover, given their ability to
alter NMDA receptor expression and activity (11,32,34,64), sigma-1
receptor agonists could be an appealing strategy for treating stroke.Table 1
Summary of protective effects following acute to subacute administration of sigma-1 pref
cerebral artery occlusion. NOS, nitric oxide synthase. ROS, reactive oxygen species. RNS,
Animal Model Sigma ligand Time of treatment
Mouse Transient MCAO (þ)-Pentazocine 5 min before reperfusion and con
for 24 h
Rat Transient MCAO PPBP Infusion following MCAO and con
during 22 h of reperfusion
Embolic MCAO PRE084 Injections 3 and 24 h post-MCAO
Focal MCAO Fluvoxamine 6 h before and immediately after
ischemic onset, or immediately a
ischemia onset and 2 h later
Permanent MCAO DTG Injections at 24, 48, and 72 h pos
Afobazole Daily injections until 96 h post-M
starting at 6e48 h post-MCAO
Piglet Neonatal
hypoxic-ischemia
PPBP Infusion from 5 min to 6 h post-r
Gerbil Bilateral carotid
artery occlusion
(þ)-SKF10,047 Injections 1 and 2 h post-reperfu
followed by infusions for 3 d
Cat Transient Focal
Ischemia
PPBP Infusion 75 min after initiation o
and continued during 4 h of repeNumerous studies have shown the acute beneﬁts of sigma agonists
in multiple animal models of stroke (Table 1). Of note, in rat models
of stroke, decreased infarct volume as well as enhanced neuronal
survival have been observedwith sigma agonist treatment 24 hours
after onset of ischemia (55,65).
Other means by which sigma agonists appear to decrease ce-
rebral damage include attenuation of radical species production
and inhibition of neuro-inﬂammation. Administration of the sigma
agonist PPBP has been shown to decrease NO production in a rat
model of transient MCAO (40) as well as decrease nitrosative and
oxidative stress in a piglet model of neonatal hypoxic-ischemia
(38). The decrease in NO production is likely mediated through
modulation of NOS activity (38e40). Treatment with sigma ago-
nists following stroke has also been shown to attenuate reactive
gliosis (55) as well as increase levels of anti-inﬂammatory cytokines
and reduce pro-inﬂammatory ones (66).
In addition to neuroprotection following stroke, sigma-1 re-
ceptor activation can facilitate neuronal re-growth and functional
recovery (38,58,65,66). For example, chronic treatment with
SA4503 starting two days after transient MCAO in rats conferred
signiﬁcantly better recovery of sensorimotor function compared
with the vehicle group, without affecting infarct size (58). SA4503
also upregulated neurabin and neurexin-1 expression inmembrane
rafts in peri-infarct regions (58). As neurabin is a protein involved in
the formation of neurite outgrowth and neurexin 1 is associated
with presynaptic differentiation, this suggests that activation of
sigma-1 receptors might stimulate neural regrowth (58). The
initiation of treatment two days after stroke in this (58) and
another study (65) is the most delayed time point to show bene-
ﬁcial effects of using a sigma ligand.
With success in the preclinical realm, a phase II trial exploring the
safety and efﬁcacy of the sigma-1 agonist cutamesine (SA4503) in
patients with ischemic stroke has been conducted (67). Sixty sub-
jects were randomized between 48 and 72 hours after stroke to
receive cutamesine (1 or 3 mg/d, oral administration) or placebo for
28 days (67). Safety and efﬁcacy were assessed at baseline, at end of
treatment (day 28) and at end of follow-up (day 56). Treatment with
placebo or cutamesine at both dosages caused no signiﬁcant differ-
ence in the incidence of adverse events, suggesting cutamesine iserring and mixed sigma agonists in a variety of in vivo stroke models. MCAO, middle
reactive nitrogen species.
Major outcome Reference
tinued  Reduces infarct size through inhibition of induc-
ible NOS
(39)
tinued  Reduces infract volume in cerebral cortex and
striatum
 Decreases NO production in ischemic and non-
ischemic striatum
(40)
 Reduces infarct volume, neurological deﬁcits, and
pro-inﬂammatory cytokines
(66)
fter
 Decreases stroke volume, and improves sensori-
motor dysfunction
 Neuroprotective effects were blocked with the
selective sigma-1 receptor antagonist NE-100
(103)
t-MCAO  Decreases infarct size, neurodegeneration and
inﬂammation
(55)
CAO  Decreases infarct size, improves survival, and
enhances grip strength
(65)
esuscitation  Reduces striatal neuronal damage and ROS/RNS
stress
 Modulates neuronal NOS/postsynaptic density-
95 coupling
(38)
sion  Neuroprotection of hippocampal neurons (105)
f ischemia
rfusion
 Decreases infarct volume and improves somato-
sensory recovery
(106)
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the primary efﬁcacy measure (change in National Institutes of
Health Stroke Scale, or NIHHS) or modiﬁed Rankin Scale and Barthel
Index scores (67). Greater improvement (P < 0.05) in NIHHS scores
among moderately and severely affected patients (baseline NIHHS
7 and 10, respectively), however, were seen in post-hoc analysis
of the 3 mg/d cutamesine group compared to placebo (67). Addi-
tional studies may focus on the moderate to severe patient sub-
groups, higher dosages, and/or longer treatment durations. The
potential to treat with cutamesine or other sigma agonists at
extended times following the initial injury warrants further inves-
tigation, as the only available treatment approved for use in humans
is the administration of thrombolytics, which is limited to 6 hours
post-stroke due to the risk for hemorrhagic transformation (10).
5.2. Parkinson's disease
Sigma-1 receptors have been shown through positron emission
tomography to be downregulated in the brains of early stage Par-
kinson's disease patients (68). Recently, the sigma-1 agonist PRE084
was shown to elicit both histological and behavioral improvements
in an animal model of Parkinson's disease (60). Mice with intra-
striatal 6-hydroxydopamine lesions were treated daily with PRE084
for 5 weeks, starting on the same day as the lesion induction (60). At
the dose of 0.3 mg/kg/day, PRE084 gradually and signiﬁcantly
improved spontaneous forelimb use, along with a modest recovery
of dopamine levels and increased dopaminergic ﬁber densities
compared to saline-treated animals (60). PRE084 also upregulated
multiple neurotrophic factors, including brain derived neurotrophic
factor (BDNF) and glial cell derived neurotrophic factor (GDNF), as
well as activated the trophic factor mediators ERK 1 and 2 (ERK1/2)
and protein kinase B (Akt) (60). These ﬁndings suggest that a
restoration of synaptic connectivity may contribute to functional
recovery in Parkinson's disease (60). Of note, neuro-inﬂammation is
a signiﬁcant contributor in the pathophysiology of Parkinson's dis-
ease, and treatment with PRE084 also attenuated M1 microglial
responses induced by 6-hydroxydopamnie lesions (60).
Along with alleviating neuro-inﬂammation, sigma-1 receptors
may also attenuate dopamine-induced toxicity in Parkinson's dis-
ease (35). Endogenous dopamine can undergo both enzymatic and
auto-oxidation, generating ROS and causing degenerative damage
to dopaminergic neurons. Mori and colleagues showed that
exposing CHO cells to dopamine at a physiologically relevant con-
centration (10 mM) increased intracellular ROS inwildtype cells and
potentiated the elevated basal levels of ROS in sigma-1 receptor
knockdown cells (35). Dopamine, however, caused apoptosis only
in the latter cells (35). Moreover, the apoptosis seen by the
dopamine/sigma-1 knockdown combination was blocked by Bcl-2
overexpression (35). Since dopamine also potentiated NF-kB acti-
vation and Bcl-2 protein downregulation in sigma-1 receptor
knockdown cells (35), these results suggest that the sigma-1 re-
ceptor-NF-kB-Bcl-2 pathway plays a crucial role against dopamine-
induced apoptosis (35). Dopamine at 10 mM was also shown to
increase sigma-1 receptor expression through oxidative stress-
related mechanisms (35). These in vitro data suggest that sigma-1
receptors are one of the endogenous substrates that counteract
the dopamine cytotoxicity that would otherwise cause apoptosis.
Future work in dopaminergic neurons is needed to validate the
sigma-1 receptor response to the damaging effects caused by
dopamine and protection against developing Parkinson's disease.
5.3. Alzheimer's disease
Decreased labeling of sigma-1 receptors are observed in the
brains of patients living with Alzheimer's disease (69) and inpostmortem tissue samples (70,71). However, only Jansen and
colleagues excluded patients who had taken sigma-1 receptor-
binding drugs, which may confound these results, and should be a
consideration for future studies. Because sigma-1 receptor levels do
not change considerably in normal aging (72), future studies should
also address the etiology of this decrease and its relationship to
Alzheimer's pathology.
A genetic polymorphism of the sigma-1 receptor is associated
with lower levels of the sigma-1 receptor protein (73, 74), but ev-
idence is inconclusive regarding sigma-1 polymorphisms as risk
factors for sporadic Alzheimer's disease (75,76). Certain combina-
tions of sigma-1 receptor and apolipoprotein E (apoE) genotypes
may synergistically increase the risk of Alzheimer's disease (73),
but it may be that the inﬂuence apoE polymorphisms outweigh
sigma-1 receptor genotype in determining sporadic Alzheimer's
disease risk (77).
With its wide range of activities, induction or activation of
sigma-1 receptors could improve clinical symptoms of Alzheimer's
disease and protect against associated neuropathologic changes.
Indeed, a variety of sigma agonists protect against Ab25-35-induced
toxicity in cultured neurons (52,78) and prevent memory deﬁcits
when Ab25-35 is injected intracerebroventricularly in mice (79e81).
The importance of sigma-1 receptors in conferring a therapeutic
beneﬁt is supported by the ability of sigma-1 receptor antagonists
to block the anti-amnesic effects of the agonists (79e81).
The mechanisms of sigma-1 receptor-mediated neuroprotective
and anti-amnestic effects are not fully understood, but may include
regulation of calcium (52), modulation of Bcl-2 and caspase levels
(52,79), and attenuation of oxidative stress (79,80). Sigma-1 re-
ceptor activation may also limit the propagation of downstream
pathological cascades, because the mixed sigma-1 receptor and
muscarinic agonist ANAVEX 2-73 prevented tau hyper-
phosphorylation and Ab1-42 production in Ab25-35-treated mice by
altering glycogen synthase kinase 3b (GSK3b) activity (82). Addi-
tionally, sigma agonists may have anti-inﬂammatory effects; afo-
bazole, for instance, reduced microglial activation while
concomitantly decreasing Bax and caspase-3 levels and increasing
survival in cultured cells exposed to Ab25-35 (63).
While preclinical evidence suggests that sigma-1 receptor ago-
nists may be useful in treating Alzheimer's disease, no selective
sigma-1 agonist is currently available for clinical use. Two currently
approved drugs, donepezil and memantine, both act on sigma-1
receptors in addition to their other primary pharmacological tar-
gets, but whether any of their therapeutic effects are mediated by
sigma-1 receptor activity has not been determined.
5.4. Retinal degeneration
Glaucoma, diabetic retinopathy, age-related macular degenera-
tion, and retinitis pigmentosa, despite their differing etiologies, are
all characterized by the progressive loss of retinal neurons that lead
to eventual blindness. Retinal degeneration can also occur sec-
ondary to other neurodegenerative conditions such as stroke and
Alzheimer's disease. Sigma-1 receptors have been detected in a
variety of cell types in the eye using RT-PCR and immunoblotting,
with supporting immunohistochemical data from retinal ganglion
cells (RGCs), inner segments of photoreceptors, and retinal pigment
epithelium (RPE) cells (83,84). Similar to the other neurodegener-
ative conditions reviewed here, common mechanistic defects in
retinal degeneration include increased inﬂammation, oxidative
stress, and activation of apoptotic pathways (85). Glial cells also
play an important role (85), and are amenable to intervention by
sigma-1 receptor agonists.
Numerous studies have demonstrated that sigma-1 receptor
agonists can mitigate apoptosis of RGCs in a variety of clinically
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agonist (þ)-pentazocine has been most commonly used for these
studies, where it attenuates excitotoxic cell death induced by
glutamate or homocysteine (86,87) as well as apoptosis resulting
from oxidative stress (43) in primary RGCs and RGC-5 cells. In
addition to (þ)-pentazocine, other sigma-1 receptor agonists such
as (þ)-SKF10,047 and SA4503 can also confer retinal cell protection
(54). Consistent with the speciﬁc involvement of sigma-1 receptors
in these processes, sigma-1 antagonists such as NE-100 and BD1047
attenuated the protective effects of the agonists (54,88). The
mechanisms bywhich agonists such (þ)-pentazocine can attenuate
apoptosis in these in vitro models appear to be throughmodulation
of a number of molecular and pathway targets, including intracel-
lular calcium, Bax levels, caspase-3 and caspase-9 cleavage, FasL
and TRAIL expression, and ER stress response proteins (PERK, ATF4,
ATF6, IRE1, CHOP) (43,54). Additionally, sigma-1 phosphorylation
has been shown to increase following xanthine:xanthine oxidase
(X:XO)-induced ROS production, and is attenuated by (þ)-pentaz-
ocine binding (43). This indicates that phosphorylation may
diminish sigma-1 activity (43), and further studies are needed to
understand the effect of phosphorylation in altering sigma-1 re-
ceptor activity.
The potential therapeutic relevance of the in vitro observations
described above is supported by in vivo models of diabetic retinal
degeneration. (þ)-Pentazocine can attenuate retinal cell apoptosis
in a streptozotocin (STZ)-induced diabetic mouse model as well as
in spontaneous diabetic Ins2Akita/þ mice (89). In the latter model,
intraperitoneal (i.p.) administration of (þ)-pentazocine (0.5 mg/kg)
twice a week for up to 22 weeks beginning at diabetes onset pre-
served retinal architecture, reduced apoptotic cell death, and
maintained radial organization of glia processes in Müller cells and
the number of cells in the ganglion cell layer (89). In addition,
oxidative damage to protein and lipid targets was suppressed by
(þ)-pentazocine administration, as shown by decreased elevations
of nitrotyrosine and decreased 4-hydroxynonenal levels (89). Blood
glucose levels remained high during (þ)-pentazocine treatment in
these mice, suggesting that the oxidative damage measured in this
model was secondary to hyperglycemia. Increased expression of ER
stress response genes (PERK, ATF6, IRE1, ATF4, CHOP) was also
suppressed by (þ)-pentazocine in the Ins2Akita/þ mice (43). A full
list of genes that were altered by (þ)-pentazocine in these mice is
published, and includes genes whose protein products are involved
in apoptosis, axon guidance, calcium ion binding, and cell differ-
entiation (43).
Sigma-1 receptor agonists can also mitigate retinal damage
resulting from ischemia-reperfusion injury. In these studies, the
sigma-1 receptor agonist PRE084 or the sigma-active neurosteroid
dehydroepiandrosterone sulfate (DHEA-S) were administered
intraperitoneally to rats just prior to ischemia and also immediately
after reperfusion (90). Pretreatment with the sigma-1 receptor
antagonist BD1047 prevented the protective effects of these sigma
agonists (90). Similar agonist-antagonist effects have also been
reported in a rat model of Ab retinal toxicity (91). In this study,
intravitreal delivery of PRE084 before Ab injection decreased
retinal damage, Bax level elevation, and phosphorylated JNK, all of
which were attenuated by BD1047 co-administration (91).
Evidence from sigma-1 receptor knockout mice supports the
relevance of this subtype to retinal degeneration pathways. In sigma-
1 knockout mice, retinal development appears normal, with
measurable deﬁcits observed only with advanced age, suggesting
that the functional consequences of this protein manifest primarily
under conditions of stress or accumulated damage (83,92). Consis-
tent with this idea, a recent study showed that RGC death is accel-
erated in sigma-1 receptor knockout mice compared to wildtype
following optic nerve crush, a model system for triggering apoptoticresponses similar to those seen in glaucoma (83). More extensive
characterization has also been performed in sigma-1 receptor
knockoutmicewithSTZ-induceddiabetes. Similar to the ocular crush
model, STZ treatment accelerated retinal damage in sigma-1 receptor
knockoutmice; diabetic sigma-1 knockoutmice showed fewer RGCs
and more caspase-3 positive cells compared to non-diabetic wild-
type mice, while sigma-1 knockout alone had no effects (92). Addi-
tionally, relative to the other groups tested (non-diabetic knockout,
non-diabetic wildtype and diabetic wildtype), diabetic sigma-1 re-
ceptor knockout mice showed increased intraocular pressure and
deﬁcits in scotopic threshold responses, which are themost sensitive
electroretinogram (ERG) responses observable with dim stimuli in
the dark-adapted state and reﬂect RGC health (92). When primary
RGCs fromwildtype and sigma-1 knockoutmicewere culturedunder
X:XO-induced oxidative stress, (þ)-pentazocine could not prevent
oxidative stress-induced cell death in the sigma-1 knockout group,
but conferred protection against cell death in the wildtype group,
conﬁrming that the protective effects of (þ)-pentazocine were
sigma-1dependent (92). Together, theseﬁndings suggest that sigma-
1 receptors contribute to tissue maintenance and resistance to
stressors or homeostatic imbalance.
In addition to effects on retinal neurons, a recent study also
evaluated the effects of (þ)-pentazocine on retinal microglia iso-
lated from rat pups. Inﬂammation was induced using LPS under
conditions that did not affect cell viability or sigma-1 receptor
expression, but did alter the cell morphology (93). (þ)-Pentazocine
was able to mitigate LPS-induced formation of NO and intracellular
ROS as well as release of pro-inﬂammatory cytokines, including
tumor necrosis factor alpha, IL-10, andMCP-1 (93). (þ)-Pentazocine
also inhibited LPS-induced ERK and JNK phosphorylation, sug-
gesting it may confer these protective effects through modulation
of the mitogen-activated protein kinase (MAPK) signaling pathway,
which has been implicated in controlling the expression of these
immune-related factors in microglia (93). The sigma-1 receptor
antagonist BD1063 prevented the protective effects conferred by
(þ)-pentazocine (93), conﬁrming the sigma-1 receptor speciﬁcity
of these effects. These results suggest that the protective effects of
sigma-1 receptor agonists in the retina may involve modulation of
glial responses in addition to effects on neurons.
One limitation of the studies conducted thus far is that they
have all focused on histology and analysis of a limited number of
biochemical markers. Functional assessments, such as ERG mea-
surements, were conducted in only one study (92). Moreover, the
most relevant in vivo interventions were begun at disease onset
and it is unclear whether protective or restorative effects are
possible if the interventions had been delayed to a later point in the
disease progression.
5.5. ALS
ALS is characterized by the progressive loss of MNs in the spinal
cord, brainstem and motor cortex causing paralysis and ultimately
death. Sigma-1 receptors are enriched in MNs (94), and mutations
in the sigma-1 receptor gene have been found in patients with
frontotemporal lobar degeneration (FTLD)-ALS and a juvenile form
of ALS (48,49). More recently, a signiﬁcant reduction in the overall
levels of the sigma-1 receptor protein has been reported in the
lumbar spinal cord of ALS patients (95). In addition, the alpha MNs
of ALS patients showed abnormal accumulation of sigma-1 re-
ceptors in ER structures and enlarged C terminals (specialized re-
gions of synaptic input within MNs in the spinal cord) (95). These
ﬁndings suggest that aberrant modiﬁcations of sigma-1 receptors
may contribute to the pathogenesis of ALS. Attempts to target
sigma-1 receptors to treat ALS have yielded promising results using
both in vitro and in vivo models.
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was shown to slow the progression of ALS symptoms and prolong
life-span (11). Daily administration of PRE084 (0.25 mg/kg, i.p.)
from 8 to 16 weeks of age improved spinal MN function, demon-
strated by the preservation of neuromuscular connections andMNs
in the spinal cord, maintenance of muscle action potential ampli-
tudes, and improvement of locomotor performance (11). Delayed
treatment with PRE084 from 12 weeks of age, which marks the
beginning of the classical symptomatic phase in SOD1G93A mice and
mimics the time point at which patients might start treatment, also
improved motor function and MN survival compared to untreated
mice (11). Additionally, sigma-1 receptor agonists may be effective
in cases of ALS not linked to SOD1 mutations, as chronic treatment
with PRE084 (0.25 mg/kg, i.p. three times a week for 8 weeks) has
been shown to improve MN survival and locomotor performances
in the wobbler mouse, a model of spontaneous MN degeneration
(56). In contrast, gene ablation of sigma-1 receptors caused an
earlier appearance of motor decline signs and decreased longevity
in the SOD1G93A mouse model (94).
Although the pathophysiology of ALS remains largely unknown,
pathological hallmarks include calcium dysregulation and excito-
toxicity, neuro-inﬂammation, accumulation of misfolded proteins,
and degradation of MNs (11), most of which have been shown to be
amenable to modulation via sigma-1 receptors. For example, the
MN of mice lacking sigma-1 receptors showed increased ﬁring
frequency in a SOD1G93A mouse model of ALS, suggesting that
sigma-1 receptors may act as a brake on MN excitability (94) and
decrease excitotoxic cell death. Moreover, knockdown of sigma-1
receptors in MN-like (NSC34) cells destabilized membrane lipid
rafts and disturbed ER structural integrity, leading to improper
calcium handling at the MAM (95) and implicating sigma-1 re-
ceptors in normal regulation of intracellular calcium homeostasis.
The altered ER integrity and calcium dysregulation may contribute
to a signiﬁcant induction of the UPR, compromising ubiquitin-
proteasome function by increasing the misfolded protein load, and
thereby further exacerbating misfolded protein accumulation, all of
which were also observed in the sigma-1 receptor knockdown
NSC34 cells (95). In addition, sigma-1 receptor accumulation was
observed in lumbar alpha MNs of ALS patients and SOD1G93A mice,
cultured ﬁbroblasts from ALS-8 patients with the P56S-VABP mu-
tation, and in NSC34 cells transfectedwith the P56S-VABPmutation
(95). These accumulations co-localized with VAPB (vesicle-associ-
ated membrane protein-associated protein B) in the ﬁbroblasts and
NSC34 cells with the P56S-VABP mutation (95). VABP is another ER
protein, inwhich the P56S point mutation causes severe misfolding
of the peptide and leads to formation of cytoplasmic inclusion
bodies and familial ALS (95). Since sigma-1 receptors can regulate
ERAD (96), this sigma-1 accumulation and co-localization with
aberrant protein aggregates may reﬂect a compensatory, albeit
inadequate, effort by sigma-1 receptors to clear misfolded proteins
in ALS. Importantly, activation of sigma-1 receptors by PRE084 in
P56S-VABP NSC34 cells ameliorated mutant VAPB aggregation and
increased the degradation of soluble mutant VAPB without
affecting the normal level of the wildtype proteins (95). Taken
together, these results suggest targeting sigma-1 receptors with
agonists can help ameliorate protein aggregation and inhibit dis-
ease progression by enhancing their innate chaperone activity.
With regard to neuro-inﬂammation, chronic treatment with
PRE084 has been shown to reduce immunoreactivity to the
microglial marker Iba1 (ionized calcium binding adapter molecular
1) in the lumbar spinal cord of SOD1G93A mice (11). Interestingly, in
a more recent study using the wobbler mouse model, chronic
treatment with PRE084 caused an increase in CD11b expression,
another marker for resting and active microglial cells, in the cer-
vical spinal cord (56). Further characterization of the microglialphenotype involved in this mouse model revealed an increase in
the number of cells positive for the pan-macrophage marker CD68
and cells positive for the M2 marker CD206 (56). Moreover, while
chronic treatment with PRE084 reduced GFAP immunoreactivity in
the wobbler mouse (56), it did not have any effect in the SOD1G93A
mouse (11). These data suggest that, depending on the existing
pathological state, activation of sigma-1 receptors may modulate
different inﬂammatory and reparative glial phenotypes in favor of a
pro-regenerative response.
5.6. Huntington's disease
Huntington's disease is a genetic disorder characterized by pro-
gressive motor and cognitive deﬁcits resulting from selective
neuronal loss, particularly in the striatum and cerebral cortex. The
disease is caused by an autosomal dominant mutation in the hun-
tingtin gene in which a repetitive CAG region that is normally less
than27 repeats longexpands through replication error to 35 ormore.
CAGencodes the amino acid glutamine, hence the characterizationof
Huntington's disease as a “polyglutamine” (polyQ) disease. Though
polyQ expansion occurs in all cells of an affected patient, the above
regions of the CNS are particularly sensitive to the effects of the
mutation in ways that remain poorly understood. Known patholog-
ical phenotypes include increased oxidative damage, increased
activation of astrocytes andmicroglia in addition to neuronal damage
and loss, deﬁcits in intracellular signaling pathways associated with
ER stress, and impaired protein folding and trafﬁcking (97,98)
Although no reports of huntingtin interaction with sigma-1 re-
ceptors have been reported in vivo, a recent study in a neuronal cell
line (PC6.3) showed decreased sigma-1 receptor levels in the
presence of mutant huntingtin proteins expression (99). In this cell
line, decreases in sigma-1 protein expressionwere observed in cells
expressing N-terminal huntingtin fragment proteins with 120
polyQ repeats (120Q-huntingtin) as well as cells expressing the
full-length huntingtin protein with 75 repeats (75QFL). In contrast,
sigma-1 receptor expression did not differ from controls in cells
expressing the 18Q-huntingtin N-terminal fragment protein or a
wildtype 17Q-huntingtin (17QFL).
Administration of the sigma-1 agonist PRE084 restored the def-
icits in sigma-1 receptor protein levels caused by the mutant hun-
tingtin expression in the PC6.3 neuronal Huntington's disease
model; there were no changes in sigma-1 mRNA levels, suggesting
modulation of post-transcriptional processes to restore expression
(99). PRE084 also promoted cell viability, and decreased caspase-3
cleavage and the resulting poly ADP ribose polymerase (PARP)
cleavage in mutant huntingtin-expressing cells (99). In addition, it
decreased caspase-12 (an ER-resident caspase) cleavage, presumably
attenuating ER stress through the activation of sigma-1 receptors
(99). Oxidative stress responses may also be attenuated by PRE084,
which decreased losses of SOD1, SOD2, thioredoxin 2, Bcl-XL
expression and attenuated mutant huntingtin-induced increases in
ROS levels (99). This study also demonstrated that PRE084 and
overexpression of sigma-1 receptors in control cells enhances cal-
pastatin expression (99), and that PRE084 can restore the down-
regulated levels of calpastatin and NF-kB-p65 and prevent the
decrease in NF-kB signaling in mutant huntingtin expressing cells
(99). Calpastatin is an endogenous inhibitor of calpains, which are
proteases that can cleave NF-kB-p65 and reduce the activity of NF-kB
(100). Together these data suggest PRE084 elicits neuroprotection by
modulating the calpastatin/calpain system, which positively affects
NF-kB signaling to upregulate various cellular antioxidants and
decrease ROS levels. Future studies are needed to determine
whether similar interactions and alterations occur in vivo, particu-
larly in clinical populations, as they may be amenable to therapeutic
interventions with sigma-1 receptor agonists.
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Sigma receptor ligands confer protective effects against many
pathological insults leading to neurodegeneration in vitro and
in vivo. They also confer neuroprotection in different animal
models of neurodegenerative disorders. While the majority of the
studies discussed here have used sigma-1 receptor-preferring li-
gands, in some cases such as stroke and Ab-induced neurotoxicity,
agonists with high sigma-1 and sigma-2 binding afﬁnities (partic-
ularly DTG and afobazole) have also proven beneﬁcial. The role of
the sigma-2 subtype remains understudied and poorly understood
due to the paucity of experimental tools; future investigation in this
area are needed.
Several recent studies also demonstrate that abnormal modi-
ﬁcation of sigma-1 receptors may contribute to the pathogenesis
of neurodegenerative diseases (Table 2). For example, mutations in
the sigma-1 receptor gene are reported in ALS (48,49), and sigma-
1 receptors accumulate in abnormal intracellular protein deposits
in various neurodegenerative diseases (95,101). Since sigma-1
receptors have chaperone and regulatory roles (4,41,96), this
accumulation may reﬂect a failed adaptive response to clear the
inclusions during the course of the various diseases. Moreover,
this accumulation may contribute to disease progression by
limiting the number of soluble sigma-1 receptors, which can in
turn predispose cells to further ER stress and subsequent
apoptosis. It is thus likely that sigma-1 receptor dysfunction par-
ticipates somewhere downstream rather than upstream of the
pathologic process, when neurodegeneration has begun but may
or may not havemanifested in clinical symptoms. Pharmacological
activation of sigma-1 receptors has been shown to help induce the
clearance of speciﬁc protein aggregates and alleviate ER stress
exerted by the aggregates (95). Further work is needed to char-
acterize the potential for using sigma-1 receptor ligands to slow
the progression of neurodegeneration and/or reverse an existing
pathology. Clarifying the cellular mechanisms and molecular tar-
gets of sigma-1 receptors in the CNS will also be critical to un-
derstanding the physiological roles and pathological alterations of
sigma-1 receptors.Table 2
Summary of abnormal modiﬁcations of sigma-1 receptors in human samples with neur
lobar degeneration. ER, endoplasmic reticulum. VAPB, vesicle-associated membrane pro
Disease Sample Major ﬁndings
Parkinson's
disease (PD)
Brain of live patients  [11C]SA4503 PET showed
less affected side of the an
 No signiﬁcant difference i
Alzheimer's
disease (AD)
Brain of live patients  [11C]SA4503 PET showed
occipital lobes, cerebellum
Hippocampal brain tissue  Reduced [3H]DTG binding
correlates with loss of pyr
Cortical brain tissue  Decreased sigma-1 recept
Amyotrophic lateral
sclerosis (ALS)
Brains tissue; lymphocytes  Mutations in the 30-untra
three ALS-FTLD/FTLD fam
 Brains of c.672*51G > T ca
activating response eleme
 Postulated that mutations
leads to a pathogenic alte
Lymphocytes  Missense mutation in exon
patients with juvenile ALS
domain of the encoded pr
 In motor neuron-like (NSC
subcellular distribution of
Lumbar spinal cord;
skin ﬁbroblasts with
P56S-VAPB mutation (ALS8)
 Reduced levels of sigma-1
 Abnormal sigma-1 recepto
motor neurons
 Accumulations co-localize
neurons and patient's ﬁbr
 Accumulations also co-locThe evidence presented here predominately supports the hy-
pothesis that sigma-1 receptor activation confers speciﬁc neuro-
protective and/or neurorestorative effects. Conversely, disruption
of the sigma-1 receptor gene is associated with deleterious effects.
In some in vitro and in vivomodels of neurodegeneration, however,
the putative sigma-1 receptor antagonist haloperidol has protective
effects, including attenuation of glutamate released during in vitro
ischemia (anoxia without glucose) (31), protection against
glutamate-induced cell death in amouse hippocampal cell line (HT-
22) (102), and reduction in infarct volume in a rat model of tran-
sient MCAO (102). The protective potency of haloperidol positively
correlates with its afﬁnity to sigma-1 receptors when compared to
other butyrophenone compounds (102); however, haloperidol has
nanomolar afﬁnity to other targets, including dopamine, serotonin,
and alpha adrenergic receptors, making it difﬁcult to attribute
sigma-1 receptor antagonism as the primary drug mechanism in
these models. Moreover, very few other studies have found bene-
ﬁcial effects using more selective sigma-1 receptor antagonists,
further weakening the hypothesis that sigma-1 receptor antago-
nism is a primary mechanism contributing to the neuroprotective
effects of haloperidol. Hence, though select compounds with
sigma-1 antagonism activity may be beneﬁcial in certain condi-
tions, the bulk of the collected data to date indicate that sigma-1
agonist-based therapeutics are more likely to protect against neu-
rodegeneration than antagonists.
While reported beneﬁcial effects of selective sigma-1 ligands in
the treatment of neurodegeneration are numerous in preclinical
studies, the U.S. Food and Drug Administration (FDA) has not
approved any selective sigma-1 receptor ligands for use in humans.
In addition, in the single clinical study that tested a selective sigma
ligand for treatment of neurodegeneration, the sigma-1 agonist
SA4503 failed to elicit signiﬁcant functional recovery in the subject
population as a whole compared to the placebo group after
ischemic stroke (67). It remains unclear why sigma-1 receptor li-
gands have been ineffective against neurodegenerative diseases in
the clinic thus far. Future studies may need to reﬁne the patient
inclusion criteria and treatment regimen in order to optimize po-
tential therapeutic effects, particularly with regard to severity ofodegenerative disorders. PET, positron emission tomography. FTLD, frontotemporal
tein.
Reference
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despite affecting multiple mechanisms and neural cell types that
contribute to neurodegeneration, sigma-1 receptor activation as a
stand-alone treatment may not be sufﬁcient in a pathophysiolog-
ical context. To combat the complex and multi-dimensional nature
of neurodegenerative diseases, a multi-treatment approach would
likely be most beneﬁcial. Many currently marketed psychotropic
medications have signiﬁcant afﬁnity for sigma-1 receptors.
Whether or not the therapeutic effects of these medications reﬂect
actions through sigma-1 receptors in humans remains unclear, but
preclinical studies have shown that compounds such as ﬂuvox-
amine, DHEA-S and donepezil elicit neuroprotective effects in part
through activation of sigma-1 receptors, as their effects were
attenuated with sigma-1 antagonists (80,90,103). Therefore, the
repurposing or development of sigma-1 receptor active drugs, se-
lective or not, and usage of selective sigma-1 ligands as an adjunct
treatment, require further investigation as viable therapeutic ap-
proaches for treating neurodegenerative diseases.
One highly valuable feature of sigma-1 ligands is their favorable
safety proﬁles, particularly in humans. This may be due to the
modulatory action of sigma-1 receptor agonists, which appear to
function selectively only under pathological conditions while
sparing normal physiological activity, thus limiting adverse side
effects. Consistent with this notion, the selective sigma-1 receptor
agonist (þ)-pentazocine prolonged the association of sigma-1 re-
ceptors with IP3R3 under ER stress but had no affect under normal
conditions (4). In addition, the selective sigma-1 receptor agonist
PRE084 improvedmotor function and restored dopaminergic ﬁbers
in a rodent model of Parkinson's disease but had no effects in the
sham-lesioned cohort (60). In the stroke study (67) and the few
other clinical trials that have tested selective sigma ligands for
various CNS-related disorders (104), few major side effects have
been reported. The varied efﬁcacy of sigma-1 ligands for their tar-
geted indications and favorable safety proﬁle suggests that further
investigation involving clinical populations will be vital for evalu-
ating the neuroprotective potential of sigma-1 receptor ligands for
neurodegenerative conditions.
7. Conclusion
Neurodegenerative disorders as diverse as stroke, Parkinson's
disease, Alzheimer's disease, retinal degeneration, ALS, and Hun-
tington's disease may share common cellular and molecular path-
ologicalmechanisms including excitotoxicity, calcium dysregulation,
oxidative/nitrosative stress, ER stress and mitochondrial dysfunc-
tion. Dysfunction of glial cells may also contribute to neuro-
degeneration. Sigma-1 receptor ligands have been shown to
modulate multiple aspects of these neurodegenerative processes,
affecting neurons as well as glia. Although further work is needed to
clarify the cellular actions of sigma-1 receptors in order to provide
greater insight into their potential therapeutic roles in the broad
spectrum of neurodegenerative diseases, ﬁndings to date suggest
that sigma-1 receptors are promising targets for developing new
drugs to understand and to treat neurodegeneration.
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